低温心脏骤停患者体外生命支持后低温结局预测:HOPE评分的外部验证
本研究纳入122例接受ECLS复温的连续性低温心脏骤停患者,采集HOPE评分包含的6个独立预测因子(年龄、性别、低温机制、入院核心体温、入院血清钾、CPR持续时间),主要终点为出院存活。122例中51例存活,实际生存概率42%(95%CI 33-51%),接近验证队列的HOPE平均预测生存概率38%;Hosmer-Lemeshow检验p=0.08(未达显著),提示校准良好;ROC曲线下面积0.825(95%CI 0.753-0.897),区分度优秀;HOPE评分<0.10的阴性预测值为97%。结论认为这是HOPE评分的首次外部验证,预测在验证样本中仍准确,HOPE评分未来可能取代血清钾作为ECLS复温的分诊工具。
要点
- 验证队列122例接受ECLS复温的低温心脏骤停患者中51例出院存活,实际生存概率42%(95%CI 33-51%)。
- 验证队列HOPE评分平均预测生存概率38%,与实际42%接近;Hosmer-Lemeshow检验p=0.08,提示校准良好。
- ROC曲线下面积0.825(95%CI 0.753-0.897),确认模型区分度优秀。
- HOPE评分<0.10的阴性预测值为97%,可用于识别ECLS复温后存活概率极低的患者。
- 作者认为HOPE评分未来可能取代血清钾作为考虑ECLS复温时的分诊工具。
适用人群与场景
- 接受ECLS复温的连续性低温心脏骤停患者,共122例。
诊断标准与关键阈值
- HOPE评分包含6个独立预测因子:年龄、性别、低温机制、入院核心体温、入院血清钾水平、CPR持续时间。
研究设计与关键结果
- 研究类型为外部验证;样本量122例;人群为接受ECLS复温的低温心脏骤停患者;主要终点为出院存活。
- 122例中51例存活,实际生存概率42%(95%CI 33-51%);验证队列HOPE评分平均预测生存概率38%。
- Hosmer-Lemeshow检验比较实际与HOPE预测生存概率,p=0.08,未达显著,提示校准良好。
- ROC曲线下面积0.825(95%CI 0.753-0.897),确认模型区分度优秀。
- HOPE评分<0.10的阴性预测值为97%。
证据类型、等级与局限
- 证据类型:外部验证研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为HOPE评分在验证样本中预测仍准确,未来可能取代血清钾作为考虑ECLS复温低温心脏骤停患者时的分诊工具。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
AIMS: The HOPE score, based on covariates available at hospital admission, predicts the probability of in-hospital survival after extracorporeal life support (ECLS) rewarming of a given hypothermic cardiac arrest patient with accidental hypothermia. Our goal was to externally validate the HOPE score.
METHODS: We included consecutive hypothermic arrested patients who underwent rewarming with ECLS. The sample comprised 122 patients. The six independent predictors of survival included in the HOPE score were collected for each patient: age, sex, mechanism of hypothermia, core temperature at admission, serum potassium level at admission and duration of CPR. The primary outcome parameter was survival to hospital discharge.
RESULTS: Overall, 51 of the 122 included patients survived, resulting in an empirical (global) probability of survival of 42% (95% CI = [33-51%]). This was close to the average HOPE survival probability of 38% calculated for patients from the validation cohort, while the Hosmer-Lemeshow test comparing empirical and HOPE (i.e. estimated) probabilities of survival was not significant (p = 0.08), suggesting good calibration. The corresponding area under the receiver operating characteristic curve was 0.825 (95% CI = [0.753-0.897]), confirming the excellent discrimination of the model. The negative predictive value of a HOPE score cut-off of <0.10 was excellent (97%).
CONCLUSIONS: This study provides the first external validation of the HOPE score reaching good calibration and excellent discrimination. Clinically, the prediction of the HOPE score remains accurate in the validation sample. The HOPE score may replace serum potassium in the future as the triage tool when considering ECLS rewarming of a hypothermic cardiac arrest victim.
参考来源
- Pasquier M, Rousson V, Darocha T, et al. Hypothermia outcome prediction after extracorporeal life support for hypothermic cardiac arrest patients: An external validation of the HOPE score. Resuscitation. 2019. PMID: 30940473. doi:10.1016/j.resuscitation.2019.03.017
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。